Clinical Trials Browser

INDUSTRY × Carcinoma, Squamous Cell × Cetuximab × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT03387111 2024-08-05

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Phase 1/2 Terminated

4 enrolled 14 charts

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT02499120 2023-09-08

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Phase 2 Completed

125 enrolled 21 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02252042 2023-07-17

MK-3475-040

Phase 3 Completed

495 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Phase 1 Terminated

13 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02633800 2019-01-07

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Phase 2 Terminated

87 enrolled 13 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms by Site

NCT01252628 2018-05-16

Phase 1 and 2 Study of PX-866 and Cetuximab

Phase 1/2 Completed

178 enrolled

Gastrointestinal

Carcinoma, Squamous Cell, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Colorectal Neoplasms

NCT01142869 2017-05-08

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Terminated

133 enrolled

Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

NCT00514943 2016-07-26

BIBW 2992 (Afatinib) in Head & Neck Cancer

Phase 2 Completed

124 enrolled 31 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01075841 2014-07-02

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Withdrawn

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Clinical Trials

FIERCE-HN

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

MK-3475-040

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Phase 1 and 2 Study of PX-866 and Cetuximab

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

BIBW 2992 (Afatinib) in Head & Neck Cancer

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck